|
Aptamer Group PLC on Friday announced new contracts as it expects annual revenue to further grow. The York, England-based synthetic binders developer said it won two ‘key’ contracts worth £192,000, which it said demonstrated momentum with ‘major’ global pharmaceutical companies and commercial traction with its proprietary Optimer platform. ‘These new contracts, coming on top of a series of wins over the past year, reflect Aptamer’s strategy to target material future revenues through royalties and monetising IP in the medium to long term, whilst delivering short term revenues and working capital from fee-for-service revenues,’ Aptamer said. The company added that its order book reached £1.95 million with the contract wins. Aptamer expects revenue for the current financial year running to the end of June 2026 to exceed financial’s 2025 revenue of £1.2 million, which had been up 40% from £860,000 in financial 2024. Chief Executive Officer Arron Tolley said: ‘We are repeatedly securing business with top-tier pharmaceutical companies with progression to higher value therapeutic applications, as shown in our liver fibrosis and our recent radiopharmaceutical delivery programmes. These partners have countless alternatives, but they choose to work with us repeatedly because our Optimer binders deliver superior results. ‘With £1.95 million in binding contracts secured and substantial opportunities in our pipeline, we are confident of exceeding last year’s revenue performance and remain focused on continuing to build commercial momentum through the remainder of the financial year.’ Aptamer shares were 7.7% lower at 0.88 pence each on Friday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
